

## IPI-549, Selective PI3K $\gamma$

Catalog	Unit
TBI4827-5MG	5 mg
TBI4827-25MG	25 mg

### Product Details

**Formal Name:** (S)-2-Amino-N-[1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

**Molecular Formula:** C<sub>30</sub>H<sub>24</sub>N<sub>8</sub>O<sub>2</sub>

**Formula Weight:** 629.68

**CAS Number:** 1693758-51-8


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to at least 25 mg/ml)

**Storage:** -20°C

**Stability:**  $\geq$  1 year.



### Applications

Selective PI3K $\gamma$

### Functions

IPI-549 is a potent and highly selective inhibitor of PI3K- $\gamma$  in both biochemical (IC<sub>50</sub> = 16 nM) and cellular (IC<sub>50</sub> = 12.2 nM) assays. Macrophage PI3K- $\gamma$  has been found to be a critical switch between immune stimulation and suppression. IPI-549 has been used to reshape tumor immune microenvironments and promote cytotoxic T-cell-mediated tumor regression. Resistance to immune checkpoint blockade in 4T1 and B16-GMCSF tumors was overcome when anti-PD-1 or anti-CTLA4 therapies were combined with PI3K- $\gamma$  inhibition via IPI-549. IPI-549 mono-treatment also resulted in tumor growth inhibition in several cancer cell lines. IPI-549 has also been shown to modulate P-glycoprotein-mediated multidrug resistance.

### Application Procedures

First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 1 month.

**For research use only.**